A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bevacizumab
/ administration & dosage
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Cohort Studies
Doxorubicin
/ administration & dosage
HIV Infections
/ complications
Humans
Male
Middle Aged
Patient Safety
Pilot Projects
Polyethylene Glycols
/ administration & dosage
Progression-Free Survival
Sarcoma, Kaposi
/ drug therapy
Treatment Outcome
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 07 2019
15 07 2019
Historique:
received:
29
10
2018
revised:
11
01
2019
accepted:
08
04
2019
pubmed:
14
4
2019
medline:
23
9
2020
entrez:
14
4
2019
Statut:
ppublish
Résumé
VEGF-A is important in the pathogenesis of Kaposi sarcoma, and bevacizumab has a response rate of 31%. We explored the combination of bevacizumab with liposomal doxorubicin in patients with Kaposi sarcoma. Patients with Kaposi sarcoma requiring systemic therapy were enrolled in one of two cohorts. Cohort 1 included patients with human immunodeficiency virus (HIV)-negative Kaposi sarcoma or with HIV-associated Kaposi sarcoma who would not be expected to respond to antiretroviral therapy (ART) alone (i.e., either stable or progressive Kaposi sarcoma on ART). Cohort 2 included all other patients with HIV-associated Kaposi sarcoma. Patients were treated with six cycles of liposomal doxorubicin with bevacizumab every 3 weeks followed by up to 11 cycles of bevacizumab alone. Sixteen patients were enrolled: 10 (two HIV negative) in cohort 1 and six in cohort 2. Fourteen patients had advanced disease (AIDS Clinical Trials Group T Pegylated liposomal doxorubicin in combination with bevacizumab has activity in advanced Kaposi sarcoma, but it is unclear whether the combination yields better outcomes than liposomal doxorubicin used alone.
Identifiants
pubmed: 30979736
pii: 1078-0432.CCR-18-3528
doi: 10.1158/1078-0432.CCR-18-3528
pmc: PMC6635024
mid: NIHMS1527088
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
liposomal doxorubicin
0
Bevacizumab
2S9ZZM9Q9V
Polyethylene Glycols
3WJQ0SDW1A
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4238-4247Subventions
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIC SC006537-23
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
J Clin Oncol. 1998 Feb;16(2):683-91
pubmed: 9469358
J Natl Cancer Inst. 2011 May 4;103(9):753-62
pubmed: 21483021
N Engl J Med. 2018 Mar 15;378(11):1029-1041
pubmed: 29539283
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
Clin Cancer Res. 1999 Oct;5(10):2963-70
pubmed: 10537366
Oncologist. 2007 Jan;12(1):114-23
pubmed: 17227906
Ann Hematol. 2005 Aug;84(8):510-6
pubmed: 15834569
Clin Infect Dis. 2008 Aug 1;47(3):410-7
pubmed: 18582203
Nat Rev Clin Oncol. 2011 Mar 08;8(4):194
pubmed: 21451496
J Clin Oncol. 2007 Nov 20;25(33):5180-6
pubmed: 18024865
Oncogene. 1995 May 18;10(10):2007-16
pubmed: 7761101
Clin Cancer Res. 2004 Aug 1;10(15):4998-5003
pubmed: 15297400
J Invest Dermatol. 1999 Dec;113(6):1047-53
pubmed: 10594750
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
J Clin Oncol. 2014 Feb 10;32(5):409-14
pubmed: 24378415
J Clin Oncol. 2012 May 1;30(13):1476-83
pubmed: 22430271
Front Microbiol. 2012 Mar 02;3:73
pubmed: 22403576
J Biol Chem. 1999 Sep 24;274(39):27617-22
pubmed: 10488101
Blood. 1999 Jun 15;93(12):4034-43
pubmed: 10361100
J Clin Oncol. 1989 Sep;7(9):1201-7
pubmed: 2671281
AIDS. 1996 Feb;10(2):175-80
pubmed: 8838705
Cancer. 2010 Aug 15;116(16):3969-77
pubmed: 20564162
JAMA. 2011 Feb 2;305(5):487-94
pubmed: 21285426
Mod Pathol. 2000 Feb;13(2):180-5
pubmed: 10697276
Blood. 2007 Dec 15;110(13):4165-71
pubmed: 17846226
Am J Pathol. 2002 Jan;160(1):23-9
pubmed: 11786394
J Clin Oncol. 1998 Mar;16(3):1112-21
pubmed: 9508198
J Clin Oncol. 2003 Aug 1;21(15):2876-82
pubmed: 12885804
AIDS. 1999 Dec 24;13(18):2583-8
pubmed: 10630528
J Clin Oncol. 1996 Aug;14(8):2353-64
pubmed: 8708728
J Natl Compr Canc Netw. 2019 Feb;17(2):171-189
pubmed: 30787130
Nature. 1998 Jan 1;391(6662):86-9
pubmed: 9422510
Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):979-84
pubmed: 9023368
AIDS. 2004 Aug 20;18(12):1737-40
pubmed: 15280789
Nat Rev Clin Oncol. 2009 Jun;6(6):327-38
pubmed: 19483739
J Clin Oncol. 2016 Dec;34(34):4125-4131
pubmed: 27863194
J Clin Oncol. 1998 Jul;16(7):2445-51
pubmed: 9667262
Infection. 2005 Jun;33(3):140-7
pubmed: 15940415
HIV Clin Trials. 2001 Sep-Oct;2(5):429-37
pubmed: 11673818
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):150-7
pubmed: 22395672
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879